Soomin Ahn, Junghye Lee, Min-Sun Cho, Sanghui Park, Sun Hee Sung1. 1. From the Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea (Dr Ahn); and the Department of Pathology, Ewha Womans University Medical Center, Seoul, Korea (Drs Lee, Cho, Park, and Sung).
Abstract
CONTEXT: - The Ki-67 index is strongly prognostic and is used as a surrogate marker to distinguish luminal A from luminal B breast cancer types. OBJECTIVE: - To investigate differences in Ki-67 index between core needle biopsy samples and matched surgical samples in breast cancer. DESIGN: - We included patients with invasive breast cancer who did not receive neoadjuvant therapy. A total of 89 pairs of core needle biopsies and surgical specimens were collected, and the Ki-67 index was assessed in hot spot areas using an image analyzer. We applied a 14% Ki-67 index to define low versus high groups. RESULTS: - The Ki-67 index was significantly higher in core needle biopsies than in surgical specimens ( P < .001), with a median absolute difference of 3.5%. When we applied 14% as a cutoff, 16 of 89 cases (18%) showed discrepancy. Thirteen cases showed a high Ki-67 index in core needle biopsies but a low Ki-67 index in surgical samples. There were 10 cases (11.2%) that showed discordant luminal A/B types between core needle biopsy and the matched surgical specimen. The reasons for the discordance were poor staining of MIB1 accompanied by fixation issues and intratumoral heterogeneity of the Ki-67 index. CONCLUSIONS: - A significant difference in the Ki-67 index between core biopsy and surgical specimens was observed. Our findings indicate that it may be better to perform the Ki-67 assay on the core needle biopsy and the surgical specimen than on only one sample.
CONTEXT: - The Ki-67 index is strongly prognostic and is used as a surrogate marker to distinguish luminal A from luminal B breast cancer types. OBJECTIVE: - To investigate differences in Ki-67 index between core needle biopsy samples and matched surgical samples in breast cancer. DESIGN: - We included patients with invasive breast cancer who did not receive neoadjuvant therapy. A total of 89 pairs of core needle biopsies and surgical specimens were collected, and the Ki-67 index was assessed in hot spot areas using an image analyzer. We applied a 14% Ki-67 index to define low versus high groups. RESULTS: - The Ki-67 index was significantly higher in core needle biopsies than in surgical specimens ( P < .001), with a median absolute difference of 3.5%. When we applied 14% as a cutoff, 16 of 89 cases (18%) showed discrepancy. Thirteen cases showed a high Ki-67 index in core needle biopsies but a low Ki-67 index in surgical samples. There were 10 cases (11.2%) that showed discordant luminal A/B types between core needle biopsy and the matched surgical specimen. The reasons for the discordance were poor staining of MIB1 accompanied by fixation issues and intratumoral heterogeneity of the Ki-67 index. CONCLUSIONS: - A significant difference in the Ki-67 index between core biopsy and surgical specimens was observed. Our findings indicate that it may be better to perform the Ki-67 assay on the core needle biopsy and the surgical specimen than on only one sample.
Authors: Laura Pons; Laura Hernández-León; Ahmad Altaleb; Esperança Ussene; Roman Iglesias; Ana Castillo; Paula Rodríguez-Martínez; Eva Castella; Vanesa Quiroga; Eudald Felip; Beatriz Cirauqui; Mireia Margelí; Pedro Luis Fernández Journal: Sci Rep Date: 2022-05-17 Impact factor: 4.996
Authors: Kristina A Tendl-Schulz; Fabian Rössler; Philipp Wimmer; Ulrike M Heber; Martina Mittlböck; Nicolas Kozakowski; Katja Pinker; Rupert Bartsch; Peter Dubsky; Florian Fitzal; Martin Filipits; Fanny Carolina Eckel; Eva-Maria Langthaler; Günther Steger; Michael Gnant; Christian F Singer; Thomas H Helbich; Zsuzsanna Bago-Horvath Journal: Virchows Arch Date: 2020-05-07 Impact factor: 4.064
Authors: Soon Bo Choi; Jung Min Park; Jee Hyun Ahn; Jieon Go; Jeeye Kim; Hyung Seok Park; Seung Il Kim; Byeong-Woo Park; Seho Park Journal: Breast Cancer Res Treat Date: 2022-01-13 Impact factor: 4.872
Authors: Okechinyere J Achilonu; Elvira Singh; Gideon Nimako; René M J C Eijkemans; Eustasius Musenge Journal: Biomed Res Int Date: 2022-01-20 Impact factor: 3.411